18th CANADIAN MELANOMA CONFERENCE 2024: Pathological Elements of Immune Responses as Opposed to Clinical How Can it be Applied to Melanoma? – Dr. Tricia Cottrell
OR
Learning Objectives
- Describe key clinical trial data from 2023 in the management of melanoma and understand the impact on Canadian practices.
- Understand the latest strategies in melanoma as they pertain to medical oncology, pathology, radiation, and surgery.
- Implement approaches that maximize patient standard of care in melanoma
Co-Chairs
Dr. Vanessa Bernstein
Dr. Teresa Petrella
Speakers
Dr. Tricia Cottrell
Studies/trials discussed:
- Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges
- Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
- The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
- Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
- Association between pathologic response and survival after neoadjuvant therapy in lung cancer
- Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade
- Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response
- Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
- Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
- A Systematic Review and Meta-analysis
- Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade
